KRAS and non-small cell lung carcinoma: This finding confirmed that the combination of trametinib with anlotinib had a significant synergistic antiproliferative effect on different KRAS-mutant NSCLC cell lines, including H23, Calu-1, SW1573, H358, A549, SK-LU-1, H460 and SW900, in vitro (Fig. 3a–d, Supplementary Fig. 4a).